Study to Assess Droxidopa in the Treatment of Freezing Of Gait Symptoms in Patients With Parkinson's Disease

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Gait Disorders, Neurologic
Interventions
DRUG

droxidopa

Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes two crossover periods of up to a 2 week titration period followed by a 4 week treatment period,with a washout between crossover periods.

Trial Locations (2)

48322

Henry Ford West Bloomfield Hospital, West Bloomfield

T5G 0B7

University of Alberta, Movement Disorders Clinic Glenrose Rehabilitation Hospital, Edmonton

Sponsors
All Listed Sponsors
lead

Chelsea Therapeutics

INDUSTRY